Surgeons that get into the field of so-called “gender affirming care” are the bottom of the barrel.
22 October 2026
Global
In this episode, Stella O'Malley, Mia Hughes and Dr Bret Alderman turn to a blunt claim: that surgeons who move into so-called gender-affirming surgery are often among the least qualified in their field. For UK readers this lands against a backdrop of real evidence gaps. The Cass Review found the evidence base for surgical and hormonal interventions in gender medicine weak, NHS England has restricted paediatric pathways, and no UK regulator publishes surgeon-specific outcome data for these procedures. The episode raises uncomfortable questions about training, oversight and informed consent that British regulators have yet to answer fully.
The episode takes its title from a provocative claim made during the conversation: that the surgeons drawn into so-called gender-affirming surgery are not drawn from the top ranks of their profession. There is no outside guest this time, with Stella O'Malley, Mia Hughes and Dr Bret Alderman discussing between themselves what it means that a relatively new, controversial and lucrative surgical field has attracted practitioners whose pathway into it bypassed the usual competitive scrutiny applied to established specialties such as plastic, urological or reconstructive surgery. For a UK audience, this claim does not arrive in a vacuum. The Cass Review, published in 2024, examined the evidence underpinning medical and surgical pathways for gender-distressed young people and repeatedly found it to be of low quality, built on a small number of studies with short follow-up and significant risk of bias. While Cass focused on hormonal treatment for under-18s rather than genital or chest surgery specifically, the same criticism of a thin and poorly scrutinised evidence base applies to the surgical end of the pathway, which in the UK is mostly accessed by adults through NHS gender services or private providers. NHS England's own response to Cass included tightening referral routes and pausing the routine prescription of puberty blockers outside research settings, a sign that the health service itself now treats this area as one requiring far more caution than it once did. What the episode's claim adds to that picture is a workforce question rather than an evidence question: who actually performs these operations, what training and credentialing they hold, and whether patients seeking surgery, in the UK or abroad, can find meaningful, independently verified data on a surgeon's outcomes before consenting to irreversible procedures. That question sits awkwardly with UK regulatory structures. The General Medical Council sets fitness-to-practise standards for all doctors, and bodies like the Royal College of Surgeons oversee training curricula, but neither publishes procedure-specific outcome data for genital or chest reconstruction tied to gender transition in the way, for instance, cardiac surgery units are now required to report mortality figures. Patients travelling for surgery, including UK residents who go abroad because NHS waiting lists are long, fall further outside any domestic oversight entirely. The underlying concern, consistent with evidence gathered during Cass and reflected in subsequent NHS England commissioning changes, is that a field expanding faster than its evidence base and training pipelines can struggle to maintain quality control. Whether or not listeners agree with the episode's blunt framing, it points toward a genuine regulatory gap that Parliament, the GMC and the Care Quality Commission have yet to close, and one worth tracking as NHS England finalises its adult gender service specifications.
